Skip to main content
. 2012 Dec 27;7:102. doi: 10.1186/1750-1172-7-102

Table 3.

Individual patient data and primary and secondary efficacy parameter findings

Pt. #
Gender
Genotype
Body wt. (kg)
Tx duration (days)
Liver (MN)
Liver volume (mL)
Spleen (MN)
Spleen volume (mL)
Hb (g/dL)
Platelets (x 109/l)
Chito nmol/(mL*hr)
      BL EOT   BL EOT BL EOT BL EOT BL EOT BL EOT BL EOT BL EOT
1
M
N370S/unknown
102

71
0.55

1420

3.40

696

15.1

127

159

2†,Ŧ
M
N370S/IVS 2 + 1
79.4
79.4
148

0.92

1833

5.52

876
15.4
15.6
93
95
781
1396
3
F
R496H/G202R
59.8
57.4
734
1.05
0.94
1564
1345
SPX

SPX

13.8
13.4
613
521
2915
1881
4
F
N370S/L444P
126
86.8
716
0.64
0.87
1999
1890
SPX

SPX

12.9
14.4
437
311

151
5†,Ŧ
F
N370S/unknown
69.7
62.8
408
0.85
0.85
1474
1333
2.66
3.54
371
445
14.0
12.1
233
148
974
3456
6
F
N370S/L444P
86.3

75
0.73

1582

2.94

507

16.8
16.9
173
173
1165

7
M
N370S/L444P
85.0
79.5
663
0.73
0.80
1545
1593
2.19
2.68
373
425
15.5
15.6
162
127
4729
1808
8†,Ŧ
F
N370S/EXG DEL G
48.0
46.0
245
1.49
1.54
1785
1774
SPX

SPX

12.9
12.3
161
195
2887
5196
9
M
N370S/L444P
91.0
85.0
732
0.98
0.89
2224
1891
9.90
10.4
1801
1761
14.3
14.0
100
98
1619
3139
10
M
N370S/N370S
71.0

50








15.3

139



11
M
N370S/N370S
70.5
69.7
729
0.98
0.92
1729
1600

3.12

435
14.0
12.7
167
100

2156
12†,Ŧ
F
N370S/T134P
57.0
46.7
373
0.77
0.80
1100
935
SPX

SPX

13.9
11.6
271
127

862
13
M
N370S/N370S
76.3

3
0.94

1798

2.21

338

16.1

187

53

14†,Ŧ
M
N370S/K198E
70.1
70.1
190
1.04
1.11
1827
1938
2.72
3.51
382
492
15.2
12.2
160
150

4978
15†,Ŧ
M
N370S/84GG
83.6
75.3
515
1.49
1.20
3112
2258
4.66
3.77
779
568
13.3
12.4
199
149

20
16*,†,Ŧ
M
N370S/S107L
78.5
72.3
405
0.83
0.91
1627
1637
SPX

SPX

13.4
11.6
283
188
420
3645
17
F
N370S/D409H
81.2

109
1.02

2062

4.30

699

13.4

106

839

18*,†
F
N370S/L444P
59.2
57.4
741
1.33
1.19
1964
1715
2.91
3.11
344
357
13.5
12.1
177
99
1232
4113
19
M
N370S/84GG
74.7
69.6
743
0.78
0.72
1463
1254
SPX

SPX

17.0
13.1
225
155
1336
4200
20Ŧ
F
N37O/NK
51.5

112
1.04

1341

3.11

320

16.8
16.8
183
152
591
695
21
F
N370S/N370S
73.5
69.0
729
0.66
0.67
1220
1148
1.44
1.29
211
179
13.8
13.3
160
153
80
41
22*,†
F
N370S/crossover
62.5
58.2
755
1.00
1.16
1562
1687
3.57
5.11
447
595
16.4
15.4
167
111
2326
2969
23
F
N370S/unknown
82.5
68.5
718
0.93
1.00
1925
1706
5.03
6.40
830
877
16.6
16.1
104
91
389
4058
24
F
N370S/N370S
67.7
65.9
740
0.82
0.86
1391
1416
2.00
1.80
270
238
16.4
14.6
226
191
27
17
25*,†
M
N370S/1327TT
72.0
72.0
754
1.22
1.22
2191
2204
4.51
6.23
650
897
15.0
14.8
152
79
2658
8348
26*,†
F
N370S/REC NEIL
61.0
51.0
732
0.95
1.06
1444
1349
1.61
2.84
197
289
14.8
13.4
186
113
666
3500
27*,†,Ŧ
F
N370S/L444P
55.9
56.8
478
1.12
1.25
1571
1770
4.01
5.08
449
577
13.6
10.8
148
99
1872
2897
28†,Ŧ
M
N370S/1035INSG
93.7
87.7
545
1.02
1.15
2391
2530
1.43
1.94
268
340
11.3
11.1
151
155
5863
6772
29*,†
M
ND
91.2
87.3
653
0.81
1.05
1847
2291
6.67
11.1
1217
1939
15.0
15.1
98
54
241
1703
30*,†
M
ND
86.1
84.8
765
0.81
0.97
1745
2063
2.40
4.07
413
690
16.8
14.7
158
116
3398
7138
31
M
N370S/N370S
95.9
82.3
734
0.82
0.90
1964
1854
SPX

SPX

14.8
14.4
264
251

110
32†,Ŧ
M
N370S/8499
71.2
79.8
239
0.92
0.75
1638
1496
2.18
2.18
311
348
14.9
14.1
186
128
391
590
33
F
N370S/R257X
124
109
738
1.05
0.88
3274
2400
SPX

SPX

17.8
13.9
229
219
44
1071
34*,†
F
N370S/unidentified
113
109
725
0.63
0.64
1788
1733
1.74
2.96
394
642
13.6
14.6
223
135
1587
4118
35*,†
F
N370S/unidentified
89.2
68.8
725
0.52
0.85
1152
1468
2.23
3.24
398
446
15.3
14.8
149
102
132
1002
36*,†
M
N370S/unidentified
70.3
68.9
725
0.97
1.09
1704
1880
2.94
4.34
413
598
14.2
14.6
177
158
 
13834
37Ŧ
M
N370S/unknown
76.0

140
0.75

1434

2.11

320

14.7
14.4
141
141
438
510
38*,†
F
84GG/N370S
65.0
62.5
732
0.72
0.92
1162
1439
3.24
3.72
422
465
16.8
15.1
136
106
98
1271
39*,†
M
N370S/84GG
88.0
81.0
730
0.88
1.11
1932
2248
SPX

SPX

17.1
14.8
254
174
1940
10636
40
M
L444P/NA
54.4

22
0.81

1095

2.18

238

16.2

134



41
M
N370S/N370S
76.7

15
0.80

1538

1.37

210

15.9

232


38
42†,Ŧ F N370S/N370S 58.5 58.0 231 1.01 0.98 1471 1424 2.35 2.54 275 294 12.6 12.9 214 207 17 21

BL, baseline; Chito, chitotriosidase; EOT, end of treatment; Hb, hemoglobin; MN, multiples of normal; ND, not determined; SPX, splenectomy; Tx, treatment; WV, worst value. *Patients adjudicated as showing disease worsening; patients within therapeutic goals at baseline who were assessed for maintenance of therapeutic goals; Ŧpatients in whom therapeutic goals were adjudicated based on worst value (end-of-treatment) analysis. Dashes represent patients in whom useable data values were not available or analyses (i.e. therapeutic goals) were not possible.